(Loss) Earnings Per Share

12 Months Ended

Mar. 31, 2020

The following summarizes the computation of (loss) earnings per share:


	Years Ended March 31,
(in thousands, except per share data)	2020		2019		2018
Basic (loss) earnings per share:
Net (loss) income attributable to Pyxus International, Inc.	$	(264,661)	$	(70,467)	$	52,436
Shares:
Weighted Average Number of Shares Outstanding	9,148		9,054		8,989
Basic (loss) earnings per share	$	(28.93)	$	(7.78)	$	5.83

Diluted (loss) earnings per share:
Net (loss) income attributable to Pyxus International, Inc.	$	(264,661)	$	(70,467)	$	52,436
Shares:
Weighted average number of shares outstanding⁽¹⁾	9,148		9,054		8,989
Plus: Restricted shares issued and shares applicable to stock options and restricted stock units, net of shares assumed to be purchased from proceeds at average market price⁽²⁾	—		—		33
Adjusted weighted average number of shares outstanding	9,148		9,054		9,022
Diluted (loss) earnings per share	$	(28.93)	$	(7.78)	$	5.81
(1) 785 shares of common stock were owned by a wholly owned subsidiary as of March 31, 2020, 2019, and 2018.
(2) Outstanding restricted shares, shares applicable to stock options, and restricted stock units are excluded because their inclusion would have an antidilutive effect on the loss per share. The dilutive shares would have been 23 and 63 for the years ended March 31, 2020 and 2019, respectively.

Certain potentially dilutive options were not included in the computation of (loss) earnings per diluted share because their effect would be antidilutive. Potential common shares are also considered antidilutive in the event of a net loss. The number of potential shares outstanding that were considered antidilutive and that were excluded from the computation of diluted (loss) earnings per share, weighted for the portion of the period they were outstanding were as follows:


	Years Ended March 31,
	2020		2019		2018
Antidilutive stock options and other awards	427		427		427
Antidilutive stock options and other awards under stock-based compensation programs excluded based on reporting a net loss for the period	25		—		—
Total common stock equivalents excluded from diluted loss per share	452		427		427
Weighted average exercise price	$	56.64	$	60.00	$	60.00